Flamel buys Éclat and takes CEO for its own
This article was originally published in Scrip
Executive Summary
Flamel Technologies, a French drug delivery company, has acquired Éclat Pharmaceuticals of the US, a specialty pharmaceutical company focused on niche brands and generic products. Prior to the acquisition, Éclat was an affiliate of Deerfield Capital, which is Flamel's largest shareholder.